Quectel Expands IoT Wi-Fi and Bluetooth Module Portfolio, Boosting Speed and Cost Efficiency for Faster Time-to-market
Quectel Wireless Solutions, a global IoT solutions provider, today announced the introduction of three additional short-range modules to its portfolio. The modules are the FC30R, a cost-effective, industrial-grade Wi-Fi module; the FCU743R, featuring Wi-Fi 4 and Bluetooth 5.2 capabilities; and the FCM740D, an MCU with Wi-Fi 4 and Bluetooth 5.2. These modules enable customers to bring IoT devices to market more cost-effectively and with faster time to market.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241007406027/en/
Quectel expands IoT Wi-Fi and Bluetooth module portfolio, boosting speed and cost efficiency for faster time-to-market. (Photo: Business Wire)
“We’re constantly striving to provide our customers with the strongest possible portfolio across the Quectel product range,” commented Norbert Muhrer, President and CSO, Quectel Wireless Solutions. “The inclusion of these modules expands the range of options in our short-range portfolio for customers' IoT applications, empowering them to innovate in their IoT device designs and accelerate their time to market.”
The FC30R is an ultra-compact, cost-effective industrial-grade Wi-Fi module that supports IEEE 802.11 b/g/n standards. Measuring just 12.0 mm × 12.0 mm × 2.1 mm, it is perfect for size-sensitive applications. It can be seamlessly integrated with Quectel 5G modules (RT620T series), 4G modules (EG25 series, AG35 series, EG95 series, EC21 series, EC25 series, EC20 series, EC200A series, EC200R series, EC300R-LA series), and other application processors (NXP, ST, TI, Ambarella, etc.), making it suitable for a wide range of M2M applications including EV chargers, mobile hotspots, on-board diagnostics (OBD), gateways and industrial PDAs.
The FCU743R is a USB interface, high-performance Wi-Fi 4 and Bluetooth 5.2 module that supports the 2.4 GHz and 5 GHz Wi-Fi bands and can realize high-speed, low-power WLAN wireless transmission with a maximum data transmission rate of up to 150 Mbps. With an ultra-compact size of 13.0 mm × 12.2 mm × 2.0 mm, the module is ideal for size-sensitive applications.
Surface-mount technology (SMT) makes FCU743R an ideal solution for durable and rugged designs and the low profile and small size of LCC package ensure that it can be easily embedded into size-constrained applications and provide reliable connectivity with these applications
The FCM740D is an MCU Wi-Fi 4 and Bluetooth 5.2 module, that boasts a high-performance processor with a frequency of up to 120MHz and supports IEEE 802.11b/g/n protocol and BLE 5.2. The module features built-in 256 KB SRAM and 2 MB/4 MB flash (optional), complies with WPA-PSK, WPA2-PSK and WPA3-SAE security standards. The FCM740D has an LCC + DIP form factor with an ultra-compact size of 20.3 mm × 15.8 mm × 2.7 mm, which optimizes the size and cost for customers.
With a variety of low-power modes and long connection keep-alive mechanisms, the module is perfect for smart home, industrial IoT, consumer electronics and other applications, especially home appliances, small-sized smart lighting and other applications and IoT devices with high temperature requirements, such as HVAC, dimmer, light strips, smart sockets.
Finally, two MCU Bluetooth modules, the HCM511S and HCM010S, are now available in additional variants with stronger transmit power and additional antenna options. The HCM511S-E now features 8 dBm transmit power and an RF coaxial connector and external pin antenna interface, while the HCM010S-E now offers a pin antenna, RF coaxial connector and optional PCB antenna.
Quectel’s IoT modules are developed with security at the core. From product architecture to firmware/software development, Quectel incorporates leading industry practices and standards, mitigating potential vulnerabilities with third party independent test houses and have incorporated security practices like generating SBOMs and VEX files as well as performing firmware binary analysis into the entire software development lifecycle.
Quectel will be exhibiting at MWC Las Vegas 2024. Schedule a meeting to find out more about the Quectel product range.
About Quectel
Quectel’s passion for a smarter world drives us to accelerate IoT innovation. A highly customer-centric organization, we are a global IoT solutions provider backed by outstanding support and services. Our growing global team of 5,600 professionals sets the pace for innovation in cellular, GNSS, Wi-Fi and Bluetooth modules as well as antennas and services.
With regional offices and support across the globe, our international leadership is devoted to advancing IoT and helping build a smarter world.
For more information, please visit: www.quectel.com, LinkedIn, Facebook, and X.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241007406027/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Announces US FDA Approval of ALYFTREK™,a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis20.12.2024 21:46:00 CET | Press release
- ALYFTREK™ is approved for patients 6 years and older with at least one responsive mutation, including 31 additional mutations not responsive to other CFTR modulator therapies - - In head-to-head clinical trials, ALYFTREK was non-inferior on ppFEV1 and further decreased sweat chloride compared to TRIKAFTA® - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has approved ALYFTREK (vanzacaftor/tezacaftor/deutivacaftor), a once-daily next-in-class triple combination cystic fibrosis transmembrane conductance regulator (CFTR) modulator for the treatment of cystic fibrosis (CF) in people 6 years and older who have at least one F508del mutation or another mutation in the CFTR gene that is responsive to ALYFTREK. See below for Important Safety Information, including a Boxed Warning. “ALYFTREK is our fifth CFTR modulator to secure FDA approval and represents another significant milestone in our journey to serially innovate and t
Vertex Announces U.S. FDA Approval for TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to Include Additional Non-F508del TRIKAFTA-Responsive Variants20.12.2024 21:35:00 CET | Press release
- Approximately 300 more people with cystic fibrosis in the U.S. are now eligible for a medicine that treats the underlying cause of their disease for the first time - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) has approved the expanded use of TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) for the treatment of people with cystic fibrosis (CF) ages 2 and older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene or a mutation that is responsive to TRIKAFTA based on clinical and/or in vitro data. In addition, safety information on liver injury and liver failure has been updated from warnings and precautions to a boxed warning. With this approval, 94 additional non-F508delCFTR mutations have been added to the TRIKAFTA label, and approximately 300 additional people with CF in the U.S. are now eligible for a medicine to treat the underlying cause of their
HSBC Continental Europe Enters Into a Memorandum of Understanding Regarding Potential Sale of HSBC Assurances Vie (France) to Matmut Société d’Assurance Mutuelle20.12.2024 20:32:00 CET | Press release
Regulatory News: HSBC Continental Europe has signed a Memorandum of Understanding (‘MOU‘) regarding the potential sale of its French life insurance business, HSBC Assurances Vie (France), to Matmut Société d’Assurance Mutuelle (‘Matmut’) (the “Potential Transaction”). HSBC Assurances Vie (France) provides a wide range of life insurance solutions and services, with over 20 billion euros of outstanding assets, net income1 of 77 million euros and a Solvency II ratio of 287% in 2023. As part of the Potential Transaction, HSBC Continental Europe and Matmut would enter into a long-term arrangement for HSBC Global Asset Management (France) to continue to partner with HSBC Assurances Vie (France). HSBC Assurances Vie (France) will continue its existing distribution arrangements. The Potential Transaction would provide customers and employees of HSBC Insurance Life (France) with the opportunity to join one of the leading French mutual insurance groups, which is in full development, and forms pa
Andersen Global udvider sin ekspertise med tilføjelsen af Valora20.12.2024 17:07:00 CET | Pressemeddelelse
Andersen Global fortsætter sin udvidelse af servicetilbud gennem en samarbejdsaftale med Valora, der er en uafhængig virksomhed med speciale i levering af skræddersyede løsninger til både private og institutionelle kunder globalt. Valora har kontorer i Miami og Raleigh og desuden global tilstedeværelse i Den Dominikanske Republik, Storbritannien og Caymanøerne. Valora blev grundlagt i 2011 af partneren Luis de Leon og tilbyder et stort udvalg af tjenester, blandt andet værdiansættelse, performance, regnskab og administration, global enhedsstyring, fondsvirksomhed og andre skræddersyede løsninger. "Et samarbejde med Andersen passer godt til både vores kunder og vores team," siger Luis. "Synergierne mellem for vores servicetilbud vil sætte os i stand til at levere omfattende og integrerede løsninger med stadigt stigende global rækkevidde." Global Chairman og CEO for Andersen Mark L. Vorsatz udtaler: "Valoras team og virksomhedskultur er, sammen med deres fokus på det praktiske, et godt m
SBC Medical Group Co., Ltd. Sells Two Subsidiaries20.12.2024 13:00:00 CET | Press release
On December 17, 2024, SBC Medical Group Holdings Incorporated (“SBC Medical”, or the “Company”), announced that its subsidiary, SBC Medical Group Co., Ltd. (hereinafter referred to as "SBCMG"), has decided to sell all shares of its subsidiaries, SBC Kijimadaira Resort Co., Ltd. (hereinafter referred to as "Kijimadaira") and Skynet Academy Co., Ltd. (hereinafter referred to as "SNA"), as outlined below. The decision to sell these subsidiaries was made to concentrate SBCMG's management resources on its core medical services business, in line with its strategy of prioritizing and focusing on key business areas. The subsidiaries being sold operate in the following industries: Kijimadaira: Ski resort operations SNA: Flight training operations The shares will be sold to a company wholly owned by Yoshiyuki Aikawa, the CEO of the Company. Since this transaction constitutes a related party transaction, it was deliberated and approved by the Company’s Board of Directors and Audit Committee. To e
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom